⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRVO News
CervoMed Inc. Common Stock
Form 8-K
sec.gov
CRVO
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
globenewswire.com
CRVO
CervoMed to Participate in September Investor Conferences
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO